Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Year-over-year book value per share growth
Percentile
P41
Within normal range
vs 2Y Ago
-0.9x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -21.77% |
| Q3 2025 | 41.13% |
| Q2 2025 | 6.63% |
| Q1 2025 | 146.41% |
| Q4 2024 | 6.14% |
| Q3 2024 | -48.87% |
| Q2 2024 | -21.03% |
| Q1 2024 | 17.42% |
| Q4 2023 | 23.07% |
| Q3 2023 | -45.90% |
| Q2 2023 | -84.73% |
| Q1 2023 | -373.26% |
| Q4 2022 | -62.27% |
| Q3 2022 | -77.80% |
| Q2 2022 | 133.36% |
| Q1 2022 | -65.69% |
| Q4 2021 | -46.31% |
| Q3 2021 | -27.09% |
| Q2 2021 | -22.16% |
| Q1 2021 | -18.51% |
| Q4 2020 | -23.09% |
| Q3 2020 | -17.96% |
| Q2 2020 | -12.39% |
| Q1 2020 | -6.66% |
| Q4 2019 | -15.92% |
| Q3 2019 | -10.42% |
| Q2 2019 | -9.24% |
| Q1 2019 | -11.07% |
| Q4 2018 | 117.66% |
| Q3 2018 | -14.30% |
| Q2 2018 | -28.06% |
| Q1 2018 | 61.03% |
| Q4 2017 | 18.33% |
| Q3 2017 | 52.38% |
| Q2 2017 | 76.77% |
| Q1 2017 | -55.61% |
| Q4 2016 | -33.04% |
| Q3 2016 | -24.61% |
| Q2 2016 | -22.52% |
| Q1 2016 | 28.06% |